sage-718
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Sep 24, 2018 (NCT03771586)
Timeline
Indications
Mechanism of action
Glutamate NMDA receptor; GRIN1/GRIN2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05619692 | Phase 2 | Feb 28, 2023 | Sage Therapeutics |
| NCT05655520 | Phase 3 | Dec 31, 2022 | Sage Therapeutics |
| NCT05318937 | Phase 2 | Jul 6, 2022 | Sage Therapeutics |
| NCT05358821 | Phase 2 | Jun 22, 2022 | Sage Therapeutics |
| NCT05107128 | Phase 2 | Nov 30, 2021 | Sage Therapeutics |
| NCT04602624 | Phase 2 | Dec 31, 2020 | Sage Therapeutics |
| NCT04476017 | Phase 2 | Sep 11, 2020 | Sage Therapeutics |
| NCT03787758 | Phase 1 | Feb 28, 2019 | Sage Therapeutics |
| NCT03844906 | Phase 1 | Dec 27, 2018 | Sage Therapeutics |
| NCT03770780 | Phase 1 | Nov 12, 2018 | Sage Therapeutics |
| NCT03771586 | Phase 1 | Sep 24, 2018 | Sage Therapeutics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sage Therapeutics | For profit | 11 | 11 | 3 | 2018 |
1 organizations
Page 1 / 1